EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Effectiveness and Safety of Saccharomyces boulardii CNCM I‐745 as Adjunct Therapy for Helicobacter pylori Eradication: Data From the European Registry on H. pylori Management (Hp‐ EuReg )

Olga P Nyssen iD, Laimas Jonaitis iD, Ángeles Pérez-Aísa iD, Bojan Tepes iD, Umud Mahmudov iD, Irina Voynovan, Samuel J Martínez-Domínguez iD, Luis Bujanda, Alfredo J Lucendo, Ludmila Vologzanina, Ana Garre iD, Frode Lerang und 39 weitere

Helicobacter · 2026-03 · 31 (2)

DOI: 10.1111/hel.70119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Helicobacter, online erschienen am 01.04.2026. Verfasst von Olga P Nyssen und 50 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autó…. Hauptthemen laut MEDLINE: Helicobacter Infections, Saccharomyces boulardii, Probiotics, Helicobacter pylori. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Helicobacter and Microbiota Study Group (EHMSG), Spanish Association of Gastroenterology, Centro de Investigacioacute;n Biomeacute;dica en Red de Enfermedades Hepaacute;ticas y Digestivas (CIBERehd).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Saccharomyces boulardii CNCM I‐745 (Sb) is one of the most widely used probiotics in clinical practice. The aim of this study was to assess the impact of adding Sb to Helicobacter pylori eradication therapy on treatment outcomes (effectiveness and safety) in routine European gastroenterology clinical practice. Materials and Methods Treatment‐naive cases from the European registry on H. pylori management (Hp‐EuReg) collected from 2013 to 2023 at AEG‐REDCap were analyzed. Effectiveness was assessed by modified intention‐to‐treat, by treatment and geographic regions. Multivariate analysis identified factors independently associated with eradication success and adverse event incidence.

Results

Among 69,922 cases, probiotics were used in 16,528 (24%) treatments, of which 4404 (27%) included Sb. Sb use was significantly associated with an increase in effectiveness (OR = 2.32; 95% confidence interval, 1.38–4.03; p < 0.01) only when prescribed with concomitant therapy encompassing a proton pump inhibitor plus clarithromycin‐amoxicillin‐metronidazole. In addition, a significant reduction in the overall incidence of at least one adverse event was observed in the Sb group (OR = 0.803; 0.66–0.97; p < 0.05). Specifically, diarrhea, nausea, dyspepsia, abdominal pain, asthenia, anorexia, heartburn, and dysgeusia occurred significantly less frequently with Sb. Treatment compliance was high in both groups (with and without Sb).

Conclusions

In Europe, the addition of Sb to first‐line regimens in clinical practice was associated with higher effectiveness when combined with concomitant therapy with clarithromycin‐amoxicillin‐metronidazole and with fewer overall adverse events, supporting its role as a beneficial adjunct in H. pylori eradication therapy. Registration Number ClinicalTrials.gov identifier: NCT02328131

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsSaccharomyces boulardiiProbioticsHelicobacter pyloriAnti-Bacterial AgentsHumansFemaleRegistriesTreatment OutcomeEuropeMaleDrug Therapy, CombinationMiddle AgedAdultAgedProton Pump InhibitorsClarithromycinMetronidazoleAmoxicillin

Stichwörter der Autor:innen

Helicobacter pylorisaccharomyces boulardiieffectivenesseradication therapyhp‐EuRegprobioticssafety

Substanzen

Anti-Bacterial AgentsProton Pump InhibitorsClarithromycinMetronidazoleAmoxicillin

Autor:innen und Institutionen

  • Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de…
  • Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Department of Gastroenterology, Hospital Universitario Costa del Sol, RICAPPS - Red de Investigación en Cronicidad, Atención Primaria y Prevención y Promoción de la Salud, Marbella, Spain.
  • Department of Gastroenterology, DC Rogaska, Slovenia.
  • Memorial Hospital, Baku, Azerbaijan.
  • A.S. Loginov Moscow Clinical Scientific Center, Moscow, Russia.

ORCID-Profile: Olga P Nyssen, Laimas Jonaitis, Ángeles Pérez-Aísa, Bojan Tepes, Umud Mahmudov, Samuel J Martínez-Domínguez, Ana Garre, Maja Denkovski, Emin Mammadov, Mārcis Leja, Javier Tejedor-Tejada, Jose M Huguet, Manuel Pabón-Carrasco, Gülüstan Babayeva, Jesús Barrio, Óscar Núñez, Antonietta G Gravina, Sergey Alekseenko, Blas José Gómez Rodríguez, Antonio Moreno Loro, György Miklós Buzás, Dmitry S Bordin, Antonio Gasbarrini, Oleksiy Gridnyev, Manuel Jiménez-Moreno, Pablo Parra, Leticia Moreira, Javier P Gisbert

Förderung

  • European Helicobacter and Microbiota Study Group (EHMSG)
  • Spanish Association of Gastroenterology
  • Centro de Investigacioacute;n Biomeacute;dica en Red de Enfermedades Hepaacute;ticas y Digestivas (CIBERehd)
  • European Union programme HORIZON
  • UK Research and Innovation
  • European Union programme EU4Health
  • Mayoly, Diasorin, Juviseacute;, Biocodex, and Zambon
  • Asociación Española de Gastroenterología

Zitieren

APA

Nyssen, O. P., Jonaitis, L., Pérez-Aísa, Á., Tepes, B., Mahmudov, U., Voynovan, I., Martínez-Domínguez, S. J., Bujanda, L., Lucendo, A. J., Vologzanina, L., Garre, A., Lerang, F., Abdulkhakov, S. R., Pavoni, M., Denkovski, M., Mammadov, E., Leja, M., Tejedor-Tejada, J., Huguet, J. M., …, & Hp‐EuReg investigators (2026). Real‐World Effectiveness and Safety of Saccharomyces boulardii CNCM I‐745 as Adjunct Therapy for Helicobacter pylori Eradication: Data From the European Registry on H. pylori Management (Hp‐ EuReg ). Helicobacter, 31(2). https://doi.org/10.1111/hel.70119

Vancouver

Nyssen OP, Jonaitis L, Pérez-Aísa Á, Tepes B, Mahmudov U, Voynovan I, et al. Real‐World Effectiveness and Safety of Saccharomyces boulardii CNCM I‐745 as Adjunct Therapy for Helicobacter pylori Eradication: Data From the European Registry on H. pylori Management (Hp‐ EuReg ). Helicobacter. 2026;31(2). doi:10.1111/hel.70119

BibTeX
@article{Nyssen2026,
  author = {Nyssen, Olga P and Jonaitis, Laimas and Pérez-Aísa, Ángeles and Tepes, Bojan and Mahmudov, Umud and Voynovan, Irina and Martínez-Domínguez, Samuel J and Bujanda, Luis and Lucendo, Alfredo J and Vologzanina, Ludmila and Garre, Ana and Lerang, Frode and Abdulkhakov, Sayar R and Pavoni, Matteo and Denkovski, Maja and Mammadov, Emin and Leja, Mārcis and Tejedor-Tejada, Javier and Huguet, Jose M and Fadieienko, Galyna and Tatiana, Ilchishina and Pabón-Carrasco, Manuel and Sarsenbaeva, Aiman S and Zaytsev, Oleg and Babayeva, Gülüstan and Barrio, Jesús and Areia, Miguel and Perona, Monica and Núñez, Óscar and Gravina, Antonietta G and Alekseenko, Sergey and Rodríguez, Blas José Gómez and Oğlu, Quliyev Fərid Vidadi and Ortiz-Polo, Inmaculada and Loro, Antonio Moreno and Buzás, György Miklós and Starostin, Boris D and Kupcinskas, Juozas and Bordin, Dmitry S and Gasbarrini, Antonio and Gridnyev, Oleksiy and Marcos-Pinto, Ricardo and Jiménez-Moreno, Manuel and Alonso, Mónica Sánchez and Flores, Virginia and Arteagoitia, Irene and Cano-Català, Anna and Parra, Pablo and Moreira, Leticia and Gisbert, Javier P and Hp‐EuReg investigators, Hp‐EuReg investigators},
  title = {Real‐World Effectiveness and Safety of Saccharomyces boulardii CNCM I‐745 as Adjunct Therapy for Helicobacter pylori Eradication: Data From the European Registry on H. pylori Management (Hp‐ EuReg )},
  journal = {Helicobacter},
  year = {2026},
  volume = {31},
  number = {2},
  doi = {10.1111/hel.70119}
}
Kostenlos starten →